Consensus Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
4.780 ^USD	-4.40%		+2.36%	-12.58%

05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
05-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Evolution of the Average Target: Bolt Biotherapeutics, Inc.

Evolution of the Target Price: Bolt Biotherapeutics, Inc.

Changes in Analyst Recommendations: Bolt Biotherapeutics, Inc.

21ce2179b44db9d244ccb6.tQCCy7-C4h--cFIOuNhJxoNL4DsVgihc3door3dwFNo.6myzhtTWky7OBWpPj48xj_l5kUle7lhvqald5j0yUpXbarqDz_fRdNYVOQ~47bf30d1682e50f58851c9062ad2a61d

Analysts' recommendations: Bolt Biotherapeutics, Inc.

15/05/24	Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	MT
15/05/24	Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/05/24	HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/05/24	Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
12/05/23	SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	MT
24/01/23	Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating	MT
04/10/22	HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target	MT
11/08/22	Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating	MT
11/08/22	SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8	MT
17/05/22	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating	MT
16/05/22	Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating	MT
01/02/22	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating	MT
06/01/22	Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45	MT
07/12/21	Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating	MT
10/11/21	SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating	MT
16/08/21	BOLT BIOTHERAPEUTICS : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating	MT
06/04/21	BOLT BIOTHERAPEUTICS : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating	MT
02/03/21	BOLT BIOTHERAPEUTICS : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BOLT BIOTHERAPEUTICS, INC.					+506.69%
	ARGENX SE					+22.14%
	WUXI APPTEC CO., LTD.					+41%
	INSMED INCORPORATED					+84.17%
	BIONTECH SE					+40.68%
	WUXI BIOLOGICS (CAYMAN) INC.					+36.6%
	GENMAB A/S					+37.36%
	AKESO, INC.					+43.66%
	SUMMIT THERAPEUTICS INC.					+75.95%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+22.28%
	Average					+91.05%
	Weighted average by Cap.					+41.87%